The FDA’s recent decision to remove the boxed warning from menopausal hormone therapy products has generated significant discussion about symptom management during menopause. But according to a new commentary from George Washington University dermatologist Emily Nadelmann, the decision may also prompt renewed conversations about an often-overlooked area: skin health.
Nadelmann explains how declining estrogen levels contribute to skin thinning, reduced collagen production, impaired wound healing, dryness, and increased skin fragility during and after menopause. She discusses emerging evidence on how hormone therapy may help improve skin structure and function, while emphasizing the importance of individualized risk-benefit discussions and clarifying that hormone therapy is not approved for cosmetic skin rejuvenation.
Nadelmann is available to discuss:
• What the FDA's hormone therapy decision means for women experiencing age-related skin changes
• The science behind estrogen's role in collagen production, hydration, and wound healing
• Benefits and limitations of systemic versus topical estrogen therapies
• Why dermatologists should be part of menopause care conversations
• Common misconceptions about hormone therapy and "anti-aging" claims
• The balance between quality-of-life benefits and potential risks
Nadelmann is a clinical assistant professor of dermatology at the George Washington University School of Medicine and Health Sciences and serves as chief executive director of the American Academy of Dermatology's Women's Health Expert Resource Group.
If you would like to schedule an interview, please contact Katelyn Deckelbaum at katelyn [dot] deckelbaum
gwu [dot] edu (katelyn[dot]deckelbaum[at]gwu[dot]edu).
-GW-